Washington D.C. [USA], Feb 18 (ANI): Researchers have now discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair (DDR) achieved significant tumour regression in mouse models of small cell lung cancer (SCLC).